News

Nervonik Raises $13 Million in Series A Financing

Nervonik Raises $13 Million in Series A Financing to Advance Next-Generation Peripheral Nerve Stimulation for Chronic Pain Relief

LOS ANGELES, March 4, 2025 /PRNewswire/ -- Nervonik, Inc. (Nervonik), a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system, has successfully closed a $13 million Series A funding round. The round was led by U.S. Venture Partners (USVP), with participation from Foothill Ventures, Correlation Ventures, and other investors.